Cytosorbents Corporation Receivables Turnover Ratio (CTSO), from the first quarter 2026 to the first quarter 2025 current and historic results, rankings and more - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Cytosorbents Corporation  (NASDAQ: CTSO)
 

Cytosorbents Accounts Receivables Turnover Ratio from the first quarter 2026 to the first quarter 2025

Quarterly Results, Trends, Rankings, Statistics


Cytosorbents Corporation's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the first quarter 2026 to a ratio of 4.67, above the company average. This is a clear sign of healthy business climate in the Medical Equipment & Supplies industry and improving liquidity at their respective customers, during the first quarter 2026. Average receivable collection period, for the Cytosorbents in Mar 31 2026 quarter, has decreased to 78 days, compared to 79 days, in the Dec 31 2025 quarter.

If we take a look into Healthcare sector 149 other companies have achieved higher receivables turnover ratio. While receivables turnover ratio total ranking has improved thus far to 1165, from overall ranking in the fourth quarter 2025 at 2483.

What is Receivable Turnover Ratio?
What is Cytosorbents Corporation Selling?


What is Receivable Turnover Ratio?




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CTSO Receivables Turnover Ratio (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter
Y / Y Receivable Change -6.76 % 3.15 % 11.98 % -1.02 % 13.38 %
Y / Y Revenue Change -0.95 % 41.55 % -6.63 % -7.25 % -14.24 %
Receivable Turnover Ratio (TTM) 4.67 4.6 4.27 4.47 4.55
CTSO's Total Ranking # 1165 # 2483 # 1492 # 1927 # 1466
Accounts Receivable average collection period days 78 79 85 82 80
Seq. Receivable Change -5.27 % 1.66 % -4.08 % 0.95 % 4.79 %
Seq. Revenue Change -11.95 % 6.55 % -1.68 % 7.39 % 25.82 %


Receivable Turnover Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 63
Healthcare Sector # 150
Overall Market # 1165

Receivable Turnover Ratio Statistics
High Average Low
1.01 0.63 0.3
(Mar 31 2017)   (Sep 30 2015)




  News about Cytosorbents Corporation Receivables Turnover Ratios

Balancing Innovation and Financial Hurdles CytoSorbents Journey with DrugSorb-ATR and Market Realities

: This article provides a analysis of recent developments related to CytoSorbents Corporation s new product, DrugSorb-ATR, designed to mitigate bleeding risks in heart bypass surgery patients on ticagrelor. This novel therapy emerges amid a challenging financial landscape, marked by decreasing receivable collections and a competitive medical equipment industry. This analysis integrates facts from regulatory progress, potential clinical impact, and financial challenges to present a comprehensive picture of CytoSorbents current trajectory. Regulatory Progress and Clinical Implication: CytoSorbents Corporation has made significant strides by filing a De Novo marketing application to the U.S. Food and Drug Administration (FDA) for DrugSorb-ATR. This innovative technology is tailored to reduce the severity of bleeding in patients undergoing coronary artery bypass grafting (CABG) surgery while on the anticoagulant ticagrelor, a scenario long recognized for its complexities and bleeding risk.


CTSO Company Profile • Back to CTSO Efficiency Comparisons • Compare CTSO Receivables Turnover Ratio to its Competitors

Financial Statements
Cytosorbents's Accounts Receivable $ 7 Millions Visit CTSO's Balance sheet
Cytosorbents's Sales TTM $ 35 Millions Visit CTSO's Income Statement
Sources of CTSO's Revenues Visit CTSO's Sales by Geography

Other Accounts Receivable Turnover Ratios
Medical Equipment & Supplies Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
CTSO's Receivable Turnover Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
CTSO's Growth Rates CTSO's Roa CTSO's Inventory Turnover Ratio CTSO's Dividend Comparisons
CTSO's Profitability Ratios CTSO's Roi CTSO's Asset Turnover Ratio CTSO's Dividend Growth
CTSO's Valuation Ratios CTSO's Roe CTSO's Financial Strength Ratios CTSO's Dividend Payout Ratio



Companies with similar Receivables Turnover Ratio for the quarter ending Mar 31 2026, within Healthcare Sector Receivable Turnover Ratio Revenues for 12 Months ending Mar 31 2026 Receivable at quarter ending Mar 31 2026
Corcept Therapeutics Inc  13.20 $ 769.096  Millions$ 58.264  Millions
Xoma Royalty Corporation  13.05 $ 48.555  Millions$ 3.720  Millions
Mannkind Corporation  13.00 $ 360.783  Millions$ 27.757  Millions
Lifestance Health Group Inc   12.74 $ 1,494.791  Millions$ 117.296  Millions
Chemed Corporation  12.73 $ 2,540.548  Millions$ 199.626  Millions
Milestone Scientific Inc   12.69 $ 8.337  Millions$ 0.657  Millions
Lftd Partners Inc   12.55 $ 36.955  Millions$ 2.945  Millions
Clene Inc   12.47 $ 0.134  Millions$ 0.011  Millions
Skinhealth Systems Inc   12.27 $ 295.223  Millions$ 24.052  Millions
Cytokinetics Incorporated  12.16 $ 105.815  Millions$ 8.702  Millions
Precision Biosciences Inc  11.94 $ 45.073  Millions$ 3.776  Millions
Teladoc Health Inc   11.94 $ 2,514.453  Millions$ 210.660  Millions
Option Care Health Inc   11.65 $ 5,666.577  Millions$ 486.439  Millions
Ensysce Biosciences Inc   11.55 $ 4.708  Millions$ 0.407  Millions
Crinetics Pharmaceuticals Inc   11.52 $ 18.069  Millions$ 1.569  Millions
Icu Medical Inc  11.46 $ 2,156.379  Millions$ 188.157  Millions
Nrc Health  11.42 $ 138.642  Millions$ 12.138  Millions
Nuvation Bio Inc   11.41 $ 142.121  Millions$ 12.454  Millions
Integrated Biopharma Inc  11.34 $ 47.241  Millions$ 4.165  Millions
National Healthcare Corp  11.07 $ 1,525.905  Millions$ 137.813  Millions
Vireo Growth Inc.  11.01 $ 350.469  Millions$ 31.834  Millions
Bioaffinity Technologies Inc   10.79 $ 5.660  Millions$ 0.525  Millions
Vivos Therapeutics Inc   10.73 $ 19.092  Millions$ 1.779  Millions
Veracyte Inc   10.68 $ 516.183  Millions$ 48.353  Millions
Immucell Corporation  10.51 $ 29.035  Millions$ 2.762  Millions
Kestra Medical Technologies Ltd   10.51 $ 93.819  Millions$ 8.925  Millions
Lifeloc Technologies Inc   10.41 $ 9.044  Millions$ 0.869  Millions
Monte Rosa Therapeutics Inc   10.39 $ 42.953  Millions$ 4.136  Millions
Viemed Healthcare Inc   10.33 $ 291.617  Millions$ 28.217  Millions
International Stem Cell Corporation  10.23 $ 9.286  Millions$ 0.908  Millions

Date modified: 2026-08-29T17:25:53+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.